- Home
- FMY vs VRCA Comparison
FMY vs VRCA Comparison
Compare FMY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- VRCA
- Stock Information
- Founded
- FMY 2005
- VRCA 2013
- Country
- FMY United States
- VRCA United States
- Employees
- FMY N/A
- VRCA N/A
- Industry
- FMY Finance/Investors Services
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- VRCA Health Care
- Exchange
- FMY Nasdaq
- VRCA Nasdaq
- Market Cap
- FMY 50.5M
- VRCA 40.6M
- IPO Year
- FMY N/A
- VRCA 2018
- Fundamental
- Price
- FMY N/A
- VRCA $4.42
- Analyst Decision
- FMY
- VRCA Hold
- Analyst Count
- FMY 0
- VRCA 5
- Target Price
- FMY N/A
- VRCA $60.00
- AVG Volume (30 Days)
- FMY 10.1K
- VRCA 592.0K
- Earning Date
- FMY 01-01-0001
- VRCA 11-03-2025
- Dividend Yield
- FMY 6.98%
- VRCA N/A
- EPS Growth
- FMY N/A
- VRCA N/A
- EPS
- FMY N/A
- VRCA N/A
- Revenue
- FMY N/A
- VRCA $14,704,000.00
- Revenue This Year
- FMY N/A
- VRCA $332.45
- Revenue Next Year
- FMY N/A
- VRCA $12.85
- P/E Ratio
- FMY N/A
- VRCA N/A
- Revenue Growth
- FMY N/A
- VRCA 5.72
- 52 Week Low
- FMY $10.71
- VRCA $3.82
- 52 Week High
- FMY $12.17
- VRCA $17.38
- Technical
- Relative Strength Index (RSI)
- FMY N/A
- VRCA 44.09
- Support Level
- FMY N/A
- VRCA $4.17
- Resistance Level
- FMY N/A
- VRCA $4.75
- Average True Range (ATR)
- FMY 0.00
- VRCA 0.30
- MACD
- FMY 0.00
- VRCA 0.05
- Stochastic Oscillator
- FMY 0.00
- VRCA 45.56
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.